{
    "Trade/Device Name(s)": [
        "Varelisa ReCombi ANA Screen",
        "Varelisa\u00ae ReCombi ANA Screen"
    ],
    "Submitter Information": "Phadia GmbH",
    "510(k) Number": "K083188",
    "Predicate Device Reference 510(k) Number(s)": [],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "LJM"
    ],
    "Summary Letter Date": "October 24, 2008",
    "Summary Letter Received Date": "October 29, 2008",
    "Submission Date": "",
    "Regulation Number(s)": [
        "21 CFR 866.5100"
    ],
    "Regulation Name(s)": [
        "Antinuclear antibody immunological test system"
    ],
    "Analyte Class(es)": [
        "immunology",
        "autoimmune"
    ],
    "Analyte(s)": [
        "dsDNA",
        "U1RNP (RNP70, A, C)",
        "Sm",
        "SS-A/Ro (52 kDa, 60 kDa)",
        "SS-B/La",
        "Scl-70",
        "CENP-B",
        "Jo-1"
    ],
    "Specimen Type(s)": [
        "Serum",
        "Plasma (citrate/EDTA)"
    ],
    "Specimen Container(s)": [
        "EDTA tube",
        "Citrate tube"
    ],
    "Instrument(s)/Platform(s)": [
        "Microplate reader capable of measuring OD at 450 nm and 620 nm"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme immunoassay (EIA)",
        "Enzyme-linked immunosorbent assay (ELISA)",
        "Indirect noncompetitive immunoassay"
    ],
    "Methodologies": [
        "Qualitative determination of antinuclear antibodies",
        "Immunoassay"
    ],
    "Submission Type(s)": [
        "Assay",
        "Kit"
    ],
    "Document Summary": "FDA 510(k) summary for Varelisa ReCombi ANA Screen qualitative EIA for detection of antinuclear antibodies to aid diagnosis of systemic rheumatic diseases",
    "Indications for Use Summary": "Qualitative determination of eight antinuclear antibodies in human serum or plasma to aid in diagnosis of systemic rheumatic diseases including SLE, scleroderma, mixed connective tissue disease, Sj\u00f6gren's syndrome, and polymyositis/dermatomyositis",
    "fda_folder": "Immunology"
}